89694-48-4

Basic information

• Product Name: 5-Chloro-2-methoxyphenylboronic acid
• Synonyms: RARECHEM AH PB 0263;CHEMBRDG-BB 3200964;AKOS BRN-0073;5-CHLORO-2-METHOXY-BENZENEBORONIC ACID;5-CHLORO-2-METHOXYPHENYLBORONIC ACID;5-Chloro-2-Methoxyphenylboroni;5-CHLORO-2-METHOXPHENYL BORONIC ACID;4-Chloroanisole-2-boronic acid
• CAS NO: 89694-48-4
• Molecular Formula: C₇H₈BClO₃
• Molecular Weight: 186.4
• EINECS: 618-292-9
• Product Categories: blocks;BoronicAcids;Boronic Acids & Esters;Phenyls & Phenyl-Het;Boronic Acid;Alkoxy;Aryl;Organoborons;B (Classes of Boron Compounds);Boronic Acids;Boronic Acids & Esters;Phenyls & Phenyl-Het;Benzene derivatives;Boronic Acids;Boronic Acids and Derivatives;Aryl Boronic Acids;Boronic Acids and Derivatives;Chemical Synthesis;Disubstituted Aryl Boronic Acids;Organometallic Reagents;Boronate Ester;Potassium Trifluoroborate
• Mol File: 89694-48-4.mol
• Article Data: 11

Chemical Properties

• Melting Point: 134-141 °C(lit.)
• Boiling Point: 360.2 ºC at 760 mmHg
• Flash Point: 171.6 ºC
• Appearance: White/Crystalline Powder
• Density: 1.32 g/cm³
• Vapor Pressure: 8.15E-06mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 7.58±0.58(Predicted)
• CAS DataBase Reference: 5-Chloro-2-methoxyphenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-2-methoxyphenylboronic acid(89694-48-4)
• EPA Substance Registry System: 5-Chloro-2-methoxyphenylboronic acid(89694-48-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 89694-48-4(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

Uses

Different sources of media describe the Uses of 89694-48-4 differently. You can refer to the following data:
1. Reactant for:? ;Boron-Heck arylation1? ;Suzuki-Miyaura reaction2
2. suzuki reaction

InChI:InChI=1/C7H8BClO3/c1-12-7-3-2-5(9)4-6(7)8(10)11/h2-4,10-11H,1H3

Upstream product

• 5720-06-9 2-Methoxyphenylboronic acid 
• 5419-55-6 Triisopropyl borate 
• 60633-25-2 2-bromo-4-chloroanisole 
• 688-74-4 boric acid tributyl ester 
• 121-43-7 Trimethyl borate 

Downstream Products

• 710334-84-2 2-chloro-6-(5-chloro-2-methoxy-phenyl)-pyrimidin-4-ylamine 
• 774607-79-3 4-chloro-6-(5-chloro-2-methoxy-phenyl)-pyrimidin-2-yl-amine 
• 852146-11-3 5-(2-methoxy-5-chlorophenyl)furan-2-carboxylic acid methyl ester 
• 767334-77-0 2-chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl-amine 
• 767334-80-5 4-(5-chloro-2-methoxy-phenyl)-pyridine-2,6-dicarboxylic acid diethyl ester 
• 934340-46-2 C₁₄H₁₃ClO₄ 
• 934340-49-5 C₁₅H₁₅ClO₄ 
• 934340-50-8 C₁₉H₁₅ClO₄ 
• 635305-45-2 2-(5-chloro-2-(methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 915697-41-5 4-chloro-1-methoxy-2-(2-methoxy-benzyl)-nitrobenzene 
• 774607-97-5 2-amino-4-chloro-6-(5-chloro-2-methoxyphenyl)-5-methyl-pyrimidine 
• 774607-99-7 2-amino-5-bromo-4-chloro-6-(5-chloro-2-methoxy-phenyl)-pyrimidine 
• 1002352-28-4 2,4,5-trichloro-6-(5-chloro-2-methoxy-phenyl)-pyrimidine 

Relevant articles and documents

New 5-aryl-1H-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting

We designed and synthesized 48 aryl-1H-imidazole derivatives and investigated their in vitro growth inhibitory activity in cancer cell lines known to present various levels of resistance to proapoptotic stimuli. The IC50 in vitro growth inhibitory concentration of these compounds ranged from >100 μM to single digit μM. Among the most active compounds, 2i displayed similar in vitro growth inhibition in cancer cells independent of the cells' levels of resistance to proapoptotic stimuli and was found to be cytostatic in melanoma cell lines. Compound 2i was then tested by the National Cancer Institute Human Tumor Cell Line Anti-Cancer Drug Screen, and the NCI COMPARE algorithm did not reveal any correlation between its growth inhibition profiles with the NCI database compound profiles. The use of transcriptomically characterized melanoma models then enabled us to highlight mitochondrial targeting by 2i. This hypothesis was further confirmed by reactive oxygen production measurement and oxygen consumption analysis.

Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine D4 receptor antagonists

The present invention relates to compounds of formula (I), any of it enantiomers, or any mixture thereof, or a pharmaceutically acceptable acid addition salt thereof, wherein R1, R2, R3, R4, R11, R12, R13, R14and R15each independently are hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, nitro, cyano, amino, acyl, alkylamino, dialkylamino, aminocarbonyl, or acylamino; R5 is hydrogen, alkyl, alkoxyalkyl, or phenylalkyl; X is —CH2—Z—, Z—CH2—, NH—CO—, —CO—NH—, or —CH═CH—; wherein Z is O, S, CH2, or NH; Y is O, —CH2—W—, —W—CH2—; wherein W is O, or S; and n is 0, 1 or 2. The compounds are useful in the treatment of psychotic disorders.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.